Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/10 17:21:47」(JST)

wiki en

Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.

Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).^[1]^[2] However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents.^[3] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.^[4]

Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.

References

^ Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866
^ Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.
^ Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873
^ Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 切除III期（リンパ節陽性）結腸癌に対する補助化学療法 adjuvant therapy for resected stage iii node positive colon cancer
2. ステージII大腸癌切除後患者に対する補助化学療法 adjuvant chemotherapy for resected stage ii colon cancer

English Journal

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM.Author information University of California San Francisco Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA. venook@cc.ucsf.eduAbstractPURPOSE: A greater understanding of the biology of tumor recurrence should improve adjuvant treatment decision making. We conducted a validation study of the 12-gene recurrence score (RS), a quantitative assay integrating stromal response and cell cycle gene expression, in tumor specimens from patients enrolled onto Cancer and Leukemia Group B (CALGB) 9581.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2013 May 10;31(14):1775-81. doi: 10.1200/JCO.2012.45.1096. Epub 2013 Mar 25.
PURPOSE: A greater understanding of the biology of tumor recurrence should improve adjuvant treatment decision making. We conducted a validation study of the 12-gene recurrence score (RS), a quantitative assay integrating stromal response and cell cycle gene expression, in tumor specimens from patie
PMID 23530100

Marketed therapeutic antibodies compendium.

Reichert JM.Author information Landes Bioscience, Austin, TX, USA. janice.reichert@landesbioscience.comAbstractTherapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as other countries, on a regular basis. As more mAbs become available to physicians and patients, keeping track of the number, types, production cell lines, antigenic targets, and dates and locations of approvals has become challenging. Data are presented here for 34 mAbs that were approved in either Europe or the United States (US) as of March 2012, and nimotuzumab, which is marketed outside Europe and the US. Of the 34 mAbs, 28 (abciximab, rituximab, basiliximab, palivizumab, infliximab, trastuzumab, alemtuzumab, adalimumab, tositumomab-I131, cetuximab, ibrituximab tiuxetan, omalizumab, bevacizumab, natalizumab, ranibizumab, panitumumab, eculizumab, certolizumab pegol, golimumab, canakinumab, catumaxomab, ustekinumab, tocilizumab, ofatumumab, denosumab, belimumab, ipilimumab, brentuximab) are currently marketed in Europe or the US. Data for six therapeutic mAbs (muromonab-CD3, nebacumab, edrecolomab, daclizumab, gemtuzumab ozogamicin, efalizumab) that were approved but have been withdrawn or discontinued from marketing in Europe or the US are also included.
mAbs.MAbs.2012 May-Jun;4(3):413-5. doi: 10.4161/mabs.19931. Epub 2012 Apr 26.
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as other countries, on a regular basis. As more mAbs become available to physicians and patients, keeping track of the number, types, production cell lines, antigenic targets,
PMID 22531442

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS.Author information Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA. mbertagnolli@partners.orgAbstractPURPOSE: Colorectal cancer (CRC) develops as a result of a series of accumulated genomic changes that produce oncogene activation and tumor suppressor gene loss. These characteristics may classify CRC into subsets of distinct clinical behaviors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2011 Aug 10;29(23):3153-62. doi: 10.1200/JCO.2010.33.0092. Epub 2011 Jul 11.
PURPOSE: Colorectal cancer (CRC) develops as a result of a series of accumulated genomic changes that produce oncogene activation and tumor suppressor gene loss. These characteristics may classify CRC into subsets of distinct clinical behaviors.PATIENTS AND METHODS: We studied two of these genomic d
PMID 21747089

「mab」

Edrecolomab^?
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	EpCAM (17-1A)
Clinical data
Trade names	Panorex
Identifiers
CAS Registry Number	156586-89-9
ATC code	L01XC01
(what is this?) (verify)

　　[★]

関: モノクローナル抗体

mab

abciximab
adahmumab
adalimumab
afelimomab
alemtuzumab
apolizumab
arcitumomab
basiliximab
bevacizumab
cantuzumab
certolizumab
cetolizumab
cetuximab
clenoliximab
daclizumab
デノスマブ denosumab 抗RANKL抗体
eculizumab
edrecolomab
efalizumab
epratuzumab
galiximab
gemtuzumab
ibritumomab
インフリキシマブ infliximab 抗TNF-α抗体クローン病 Ph⁺ALL
inotuzumab
keliximab
natalizumab
nebacumab
omalilzumab
omalizumab
oregovomab
palivizumab
panitumumab
pertuzumab
pexelizumab
リツキシマブ rituximab：抗CD20抗体：慢性リンパ性白血病、B細胞リンパ腫

[Lancet1994-1] Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343(8907):1177-83. PMID 7909866

[Proc2002-2] Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study (abstract). Proc Am Soc Clin Oncol. 2002;21:128a.

[3] Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002;360(9334):671-7. doi:10.1016/S0140-6736(02)09836-7 PMID 12241873

[stageII-4] Colacchio TA, Niedzwicki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol. 2004;23:251a.

匿名

検索

案内

案内

edrecolomab